Investigational drug · Phase 3
MHB018A
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Thyroid Eye Disease (TED), Thyroid Eye Disease, TED, Thyroid Associated Ophthalmopathies.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
6
Any phase or sponsor naming "MHB018A"
First trial start
2025
Jul 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MHB018A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thyroid Eye Disease (TED)
- Thyroid Eye Disease, TED
- Thyroid Associated Ophthalmopathies
Approved drugs for the same conditions: Endocrinology and women's health · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "MHB018A" as an intervention, largest first.
- Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye DiseasePivotal-lookingRecruiting
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07262476 · 258 participants (planned) · Start Jan 9, 2026 · Primary completion Jan 31, 2029
Drug: MHB018A injection · For: Thyroid Eye Disease (TED)
Sites: Shanghai, China
- Open-Label Extension Study of MHB018A in Patients With Thyroid Eye DiseasePivotal-lookingNot yet recruiting
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07620405 · 219 participants (planned) · Start Jul 2027 · Primary completion Jan 2030
Drug: MHB018A injection · For: Thyroid Eye Disease (TED)
- MHB018A Treatment in Patients With Chronic Thyroid Eye DiseasePivotal-lookingActive, not recruiting
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07257185 · 150 participants (planned) · Start Mar 17, 2026 · Primary completion Aug 31, 2027
Drug: MHB018A injection; MHB018A injection Placebo · For: Thyroid Eye Disease (TED)
Sites: Shanghai, China
- Treatment of Chronic Thyroid Eye Disease With MHB018APivotal-lookingRecruiting
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07622121 · 135 participants (planned) · Start Sep 24, 2026 · Primary completion Jul 2028
Drug: MHB018A injection; MHB018A injection Placebo · For: Thyroid Eye Disease, TED
Sites: Coral Gables, Florida
- MHB018A Treatment in Patients With Active Thyroid Eye DiseasePivotal-lookingActive, not recruiting
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT06989918 · 108 participants (planned) · Start Jul 22, 2025 · Primary completion Dec 2026
Drug: MHB018A; MHB018A placebo · For: Thyroid Associated Ophthalmopathies
Sites: Shanghai, China
- Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled StudyPivotal-lookingRecruiting
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07622108 · 84 participants (planned) · Start Sep 28, 2026 · Primary completion Jul 2028
Drug: MHB018A; MHB018A placebo · For: Thyroid Eye Disease, TED
Sites: Coral Gables, Florida
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Thyroid Eye Disease (TED)
- VRDN-003ZL-1109Phase 35 trials
Viridian Therapeutics, Inc. · Thyroid Eye Disease, Thyroid Eye Disease (TED)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.